defined risk factor in patients with gastric carcinoma. ## METHODS. Enzyme-linked immunoadsorbent assays were used to test for uPA anti-
Prognostic impact of stromal cell-derived urokinase–type plasminogen activator in gastric carcinoma
✍ Scribed by Yasushi Okusa; Takashi Ichikura; Hidetaka Mochizuki
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 99 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Urokinase-type plasminogen activator (upa) plays an important role in the destruction of the extracellular matrix and basement membrane around cancer cells. in the current study, the authors investigated upa expression in cancer cells and stromal cells in patients with gastric carcinoma.
Methods:
Upa activity was determined by an enzymatic assay using synthetic substrate (s-2444) in tumor specimens obtained from 71 patients with gastric carcinoma and was compared with the results of immunohistochemical staining for upa.
Results:
Higher upa activity was significantly associated with tumors with peritoneal metastases and tumors with deeper invasion into the gastric wall. undifferentiated tumors showed significantly higher upa activities compared with differentiated tumors. the 25 patients with high upa activity (> or = 60 u/mg protein) had a lower survival rate than the 46 patients with low upa activity (< 60 u/mg protein) (p < 0.05). upa activity showed prognostic significance in patients with international union against cancer stage ii and stage iii tumors (p < 0.05, respectively). there was no significant relation between immunohistochemical expression of upa in cancer cells and upa enzymatic activity. however, upa expression in stromal cells significantly correlated with upa activity in tumor tissues. the upa expression in stromal cells also correlated with tumor histology and peritoneal metastases.
Conclusions:
These results suggest that upa enzymatic activity is a prognostic factor in gastric carcinoma, and that upa produced by stromal cells may regulate cancer cell invasion.
📜 SIMILAR VOLUMES
Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. Consistent with its role in cancer spread, uPA has been shown to be a prognostic marker in a variety of malignancies, especially breast cancer. Approximately 20 different groups have shown
Basal cell carcinoma of the skin (BCC) is the most common cancer worldwide. Unlike most other human malignancies, BCCs rarely metastasise. In this investigation, we show that the serine protease urokinase plasminogen activator (u-PA), which is causally involved in metastasis, is expressed at lower l
The urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in tumour invasion. Previous studies have shown by RT-PCR that uPA and uPAR mRNAs are expressed in human hepatocellular carcinoma (HCC). Here, in situ hybridization, immunohistochemistry, and double immuno¯
Met protein encoded by MET oncogene is the high affinity receptor for hepatocyte growth factor (HGF)/scatter factor (SF). HGF/SF has to be cleaved in its heterodimeric form by the urokinase-type plasminogen activator (uPA) to become active as a ligand for Met receptor. The expression of Met protein
The expression of urokinase-type plasminogen activator (u-PA), its receptor (u-PAR) and metalloproteases activity were analyzed in 4 human gastric-cancer cell lines (AGS, Hs746T, SNU-1, and SNU-5), in an attempt to relate these activities to their invasive potential and tumorigenicity on the modifie